about
Nosocomial infections and immunity: lesson from brain-injured patientsPRospective Observational POLIsh Study on post-stroke delirium (PROPOLIS): methodology of hospital-based cohort study on delirium prevalence, predictors and diagnostic tools.Clinical significance of acute phase reaction in stroke patients.Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease.Systemic inflammation as a therapeutic target in acute ischemic stroke.Mechanical thrombectomy in acute stroke - Five years of experience in Poland.The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.Biochemical and Radiological Markers of Alzheimer's Disease Progression.European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischemic stroke.Knowns and Unknowns About Delirium in Stroke: A Review.Pre-stroke apathy symptoms are associated with an increased risk of delirium in stroke patients.Serum interleukin-6 predicts cortisol release in acute stroke patients.The FGA Thr312Ala polymorphism and risk of intracerebral haemorrhage in Polish and Greek populations.Reduced release of TNFα and IP-10 after ex vivo blood stimulation with endotoxin is associated with poor outcome after stroke.Emotional Decoding Abilities Do Not Influence Neuropsychiatric Disturbances in Patients With Frontotemporal Dementia.Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population.Intracerebral hemorrhage triggers interleukin-6 and interleukin-10 release in blood.Plasma endotoxin activity rises during ischemic stroke and is associated with worse short-term outcome.The association between plasma endotoxin, endotoxin pathway proteins and outcome after ischemic stroke.Reduced ex vivo release of pro-inflammatory cytokines and elevated plasma interleukin-6 are inflammatory signatures of post-stroke delirium.Dexamethasone inhibits TNF-alpha synthesis more effectively in Alzheimer's disease patients than in healthy individuals.Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.Paraoxonase gene polymorphisms and sporadic ALSRetrospective study of Creutzfeldt-Jakob disease in Belgium: neuropathological findingsDD genotype of ACE gene is a risk factor for intracerebral hemorrhageACE genotype, risk and causal relationship to stroke: implications for treatmentSerum albumin level and nosocomial pneumonia in stroke patientsParaoxonase-1 Q192R polymorphism and risk of sporadic amyotrophic lateral sclerosisIncreased plasma fibrinogen predicts one-year mortality in patients with acute ischemic strokeInterleukin 6-174G>C polymorphism and risk of aneurysmal subarachnoid hemorrhage: case-control study and meta-analysisThe AGTR1 gene A1166C polymorphism as a risk factor and outcome predictor of primary intracerebral and aneurysmal subarachnoid hemorrhagesPersonalizing acute therapies for ischemic stroke: Thrombolysis or thrombectomy?Glucocorticoid Resistance is Associated with Poor Functional Outcome After StrokeThe specific ex vivo released cytokine profile is associated with ischemic stroke outcome and improves its predictionNeutrophil count is related to stroke outcome following endovascular therapyC-reactive protein and post-stroke depressive symptoms
P50
Q24800368-ADB45476-9979-48A8-A09D-E633B93D1D64Q35755521-572D4029-E951-4EB0-802E-198B087D9002Q36992579-312F3F7E-B42F-460C-B749-A3A18A93F66EQ37092283-B3AE00DA-0C6D-4939-8060-E0FDE4D64DE6Q38417525-00921C78-63F4-404C-A8F9-CA7F2784FBE5Q38653640-7F9D9EA2-8D96-4906-9848-BAE5EBC42664Q38683919-11241928-9B1C-4C95-8E5A-0FC4D25F8E35Q38693438-CC3C7A4B-F4CA-4037-99FF-304D29760FBCQ38987914-D3CE1A31-A2B9-4D7E-BB9E-0D295E41F9F8Q39041379-3A2FDCDA-0935-451C-A9FD-CC5DE7EC9262Q40099601-1344D70C-87A4-4E94-9D1D-4CEC2DA80D4BQ44821241-1B85378C-8313-411B-BC79-AA7542911E28Q46651865-03C76D6C-B1F6-4EFA-B313-EFD78B4CE3EDQ47257843-51986D75-E5DE-4A93-8882-E7ECCAC1B327Q47663934-31CA20BB-D13D-48D4-A379-1B17700A2FF2Q48218985-7B61BADA-1A9C-48E8-A608-351506E5B242Q48491505-EBC43CD1-0E71-4419-902A-664E60960E98Q48631084-CAC4E33F-EE94-49A5-9964-0309B9B41E56Q49899599-4AAB19CD-5A03-43A3-9A26-9A56D75BB2FBQ52579937-F8AF923B-993C-46B4-9BA5-DFA1E2C25C15Q53257572-934B669A-59E6-4BA8-AB5B-26E719DCAF0BQ55467785-60B16FB7-5C0D-42A5-AFE3-87CE299A025CQ59632217-56099891-11B5-4612-A67D-2BD9CF3D4389Q73727333-0424DC9E-5300-40CC-B89C-E638EBC27594Q80385008-871BD817-AB18-4CE0-9877-BE3FAEDE2FE8Q80547471-AD2356E8-0EAF-4168-8013-DFE9DDCD3334Q83161218-DF933AFB-8DC0-49DA-9CFB-D3F8D58AADC7Q83185630-CDD97144-9D27-4810-8C37-04A06965603CQ83226695-C3A35C9E-418F-4922-A597-9E5686216829Q83630016-09C41E8B-4FB4-482F-ADEB-E565CDC4C1B9Q85208013-1F50F15B-20C5-497E-ACA3-FAAF57B490D9Q87790081-2ABA197D-DD0F-4A8B-AB99-23B176FE1E76Q89928507-67B30709-37D1-4F65-ACC9-1D17ABFF0855Q92451097-87E0BDE5-19CA-4ABC-8728-2146EF56587FQ93023705-23AD9A33-3A20-4401-A238-B738C3F1479FQ93039675-69240056-149E-4C35-9F2E-4FBE59F4AD8F
P50
description
Polish neurologist
@en
Pools onderzoeker
@nl
polski lekarz, neurolog
@pl
name
Tomasz Dziedzic
@ast
Tomasz Dziedzic
@ca
Tomasz Dziedzic
@cs
Tomasz Dziedzic
@en
Tomasz Dziedzic
@es
Tomasz Dziedzic
@ga
Tomasz Dziedzic
@gl
Tomasz Dziedzic
@hr
Tomasz Dziedzic
@hsb
Tomasz Dziedzic
@it
type
label
Tomasz Dziedzic
@ast
Tomasz Dziedzic
@ca
Tomasz Dziedzic
@cs
Tomasz Dziedzic
@en
Tomasz Dziedzic
@es
Tomasz Dziedzic
@ga
Tomasz Dziedzic
@gl
Tomasz Dziedzic
@hr
Tomasz Dziedzic
@hsb
Tomasz Dziedzic
@it
prefLabel
Tomasz Dziedzic
@ast
Tomasz Dziedzic
@ca
Tomasz Dziedzic
@cs
Tomasz Dziedzic
@en
Tomasz Dziedzic
@es
Tomasz Dziedzic
@ga
Tomasz Dziedzic
@gl
Tomasz Dziedzic
@hr
Tomasz Dziedzic
@hsb
Tomasz Dziedzic
@it
P106
P1153
6701567111
P1412
P1559
Tomasz Dziedzic
@pl
P21
P27
P31
P3124
P496
0000-0003-4086-0729